Clinical effects and tolerability of high-dose, high-frequency recombinant interferon β-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

Bibliography

• Gusev E, Boiko A, Bikova O, The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 2002;104:203-7
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Pozzilli C, Liguori M, Prospective study of multiple sclerosis with early onset. Mult Scler 2002;8:115-8
   PubMed Web of Science ®Google Scholar
• Boiko A, Vorobeychik G, Paty D, Early onset multiple sclerosis: a longitudinal study. Neurology 2002;59:1006-10
   PubMed Web of Science ®Google Scholar
• Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
   PubMed Web of Science ®Google Scholar
• Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S22-31
   PubMed Web of Science ®Google Scholar
• Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008;71:S3-7
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-8
   PubMed Web of Science ®Google Scholar
• Fisher E, Rudick RA, Simon JH, Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-20
   PubMed Web of Science ®Google Scholar
• Revel M. Interferon-beta in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 2003;100:49-62
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97
   PubMed Web of Science ®Google Scholar
• Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008;10:225
   PubMedGoogle Scholar
• Ross C, Clemmesen KM, Svenson M, Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-12
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Hurwitz B, Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-84
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM, Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91
   PubMed Web of Science ®Google Scholar
• Perini P, Calabrese M, Biasi G, The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004;251:305-9
   PubMed Web of Science ®Google Scholar
• Petkau AJ, White RA, Ebers GC, Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-38
   PubMed Web of Science ®Google Scholar
• Al-Sabbagh A, Bennett R, Kozma C, Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. Meeting Abstract, European Neurological Society [ENS], Nice, France, 7 – 11 June 2008 [P321]. J Neurol 2009;255:79
   Web of Science ®Google Scholar
• Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009;10:291-309
   PubMed Web of Science ®Google Scholar
• Liu Z, Pelfrey CM, Cotleur A, Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001;112:153-62
   PubMed Web of Science ®Google Scholar
• Kawanokuchi J, Mizuno T, Kato H, Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology 2004;46:734-42
   PubMed Web of Science ®Google Scholar
• Genc K, Dona DL, Reder AT. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997;99:2664-71
   PubMed Web of Science ®Google Scholar
• Sharief MK, Semra YK, Seidi OA, Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 2001;120:199-207
   PubMed Web of Science ®Google Scholar
• Sharief MK, Semra YK. Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis. Arch Neurol 2002;59:1115-21
   PubMed Web of Science ®Google Scholar
• Sega S, Wraber B, Mesec A, IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 2004;106:255-8
   PubMed Web of Science ®Google Scholar
• Nagai T, Devergne O, Mueller TF, Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol 2003;171:5233-43
   PubMed Web of Science ®Google Scholar
• Byrnes AA, McArthur JC, Karp CL. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002;51:165-74
   PubMed Web of Science ®Google Scholar
• van Seventer JM, Nagai T, van Seventer GA. Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells. J Neuroimmunol 2002;133:60-71
   PubMed Web of Science ®Google Scholar
• Zang YC, Skinner SM, Robinson RR, Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler 2004;10:499-506
   PubMed Web of Science ®Google Scholar
• Ossege LM, Sindern E, Patzold T, Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II. J Neuroimmunol 1998;91:73-81
   PubMed Web of Science ®Google Scholar
• Durelli L, Conti L, Clerico M, T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499-509
   PubMed Web of Science ®Google Scholar
• Zang YC, Halder JB, Samanta AK, Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol 2001;112:174-80
   PubMed Web of Science ®Google Scholar
• Lund BT, Ashikian N, Ta HQ, Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol 2004;155:161-71
   PubMed Web of Science ®Google Scholar
• Muraro PA, Leist T, Bielekova B, VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000;111:186-94
   PubMed Web of Science ®Google Scholar
• Muraro PA, Liberati L, Bonanni L, Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol 2004;150:123-31
   PubMed Web of Science ®Google Scholar
• Trojano M, Avolio C, Liuzzi GM, Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-8
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Tranquill LR, Dambrosia JM, Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-74
   PubMed Web of Science ®Google Scholar
• Graber J, Zhan M, Ford D, Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 2005;161:169-76
   PubMed Web of Science ®Google Scholar
• Kraus J, Bauer R, Chatzimanolis N, Interferon-beta1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol 2004;251:464-72
   PubMed Web of Science ®Google Scholar
• Stuve O, Dooley NP, Uhm JH, Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-63
   PubMed Web of Science ®Google Scholar
• Soilu-Hanninen M, Laaksonen M, Hanninen A, Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS. J Neuroimmunol 2005;167:175-82
   PubMed Web of Science ®Google Scholar
• Oztekin NS, Oztekin FM, Orhan G, The effects of interferons and copaxone on MMP-9/TIMP-1 ratio and TIMP-2 levels and on new enhancing lesions on magnetic resonance imaging in patients with relapsing-remitting multiple sclerosis. Meeting Abstract, Annual Meeting of the Americas Committee on Treatment and Research in Multiple Sclerosis (ACTRIMS), Montreal, 17 – 20 September 2008 [P486]. Mult Scler 2008;14:S171
   Web of Science ®Google Scholar
• Ozenci V, Kouwenhoven M, Teleshova N, Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000;108:236-43
   PubMed Web of Science ®Google Scholar
• Galboiz Y, Shapiro S, Lahat N, Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001;50:443-51
   PubMed Web of Science ®Google Scholar
• Hua LL, Kim MO, Brosnan CF, Modulation of astrocyte inducible nitric oxide synthase and cytokine expression by interferon beta is associated with induction and inhibition of interferon gamma-activated sequence binding activity. J Neurochem 2002;83:1120-8
   PubMed Web of Science ®Google Scholar
• Lucas M, Rodriguez MC, Gata JM, Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients. Neurochem Int 2003;42:67-71
   PubMed Web of Science ®Google Scholar
• Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest 1997;100:604-12
   PubMed Web of Science ®Google Scholar
• Caggiula M, Batocchi AP, Frisullo G, Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol 2006;118:77-82
   PubMed Web of Science ®Google Scholar
• Ito M, Natsume A, Takeuchi H, Type I interferon inhibits astrocytic gliosis and promotes functional recovery after spinal cord injury by deactivation of the MEK/ERK pathway. J Neurotrauma 2009;26:41-53
   PubMed Web of Science ®Google Scholar
• Azoulay D, Mausner K, Urshansky N, Interferon beta upregulates brain-derived neurotrophic factor secretion from peripheral blood mononuclear cells of relapsing-remitting multiple sclerosis patients through a CD40-dependent mechanism. Meeting Abstract, Annual Meeting of the Americas Committee on Treatment and Research in Multiple Sclerosis (ACTRIMS), Montreal, 17 – 20 September 2008 [P455]. Mult Scler 2008;14:S162
   Web of Science ®Google Scholar
• Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007;13:459-70
   PubMed Web of Science ®Google Scholar
• Freedman MS, Francis GS, Sanders EA, Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005;11:41-5
   PubMed Web of Science ®Google Scholar
• Paty DW, Boyko AN. Beta interferons delay the switch from relapsing-remitting to secondary progressive multiple sclerosis. Neurology 2000;54:A337
   Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Constantinescu C, Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
   PubMed Web of Science ®Google Scholar
• Uitdehaag BM, Kappos L, Verdun E. Continuous versus non-continuous subcutaneous interferon beta-1a treatment in relapsing-remitting multiple sclerosis: long term data from the PRISMS study. Meeting Abstract, European Neurological Society [ENS], Milan, Italy, 20 – 24 June 2009 [P346]. J Neurol 2009;256:S122-3
   Web of Science ®Google Scholar
• Uitdehaag B, Kappos L, Verdun E, Long-term treatment with subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: exploratory analysis of cumulative time and dose impact on clinical and magnetic resonance imaging outcomes. Meeting Abstract, European Neurological Society [ENS], Milan, Italy, 20 – 24 June 2009 [P347]. J Neurol 2009;256:S123
   Web of Science ®Google Scholar
• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504
   PubMed Web of Science ®Google Scholar
• Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001;56:1505-13
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin D, Francis G, Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74
   PubMed Web of Science ®Google Scholar
• Schwid SR, Thorpe J, Sharief M, Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 2005;62:785-92
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Al-Sabbagh A, Bennett R, Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study. BMC Neurol 2008;8:11
   PubMedGoogle Scholar
• Mikol DD, Barkhof F, Chang P, Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Milanese C, La Mantia L, Palumbo R, A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74:1689-92
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Rio J, Porcel J, Tellez N, Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9
   PubMed Web of Science ®Google Scholar
• Boiko AN, Davydovskaia MF, Demina TL. The experience of long-term disease modifying MS therapy in every day neurological practice in Moscow MS Center. Korsakov J Neurol Psych 2007;S4:84-94
   Google Scholar
• Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-4
   PubMed Web of Science ®Google Scholar
• Trojano M, Liguori M, Paolicelli D, Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003;9:451-7
   PubMed Web of Science ®Google Scholar
• Neilley LK, Goodin DS, Goodkin DE, Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552-4
   PubMed Web of Science ®Google Scholar
• Ruggieri RM, Settipani N, Viviano L, Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003;24:361-4
   PubMed Web of Science ®Google Scholar
• Onesti E, Bagnato F, Tomassini V, Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study. Neurol Sci 2003;24:340-5
   PubMed Web of Science ®Google Scholar
• O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
   PubMed Web of Science ®Google Scholar
• Daugherty KK, Butler JS, Mattingly M, Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc (2003) 2005;45:371-5
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Koch-Henriksen N, Ravnborg M, Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006;12:253-64
   PubMed Web of Science ®Google Scholar
• Dubois BD, Keenan E, Porter BE, Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003;74:946-9
   PubMed Web of Science ®Google Scholar
• Portaccio E, Zipoli V, Siracusa G, Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59:131-5
   PubMed Web of Science ®Google Scholar
• Mohr DC, Boudewyn AC, Likosky W, Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125-32
   PubMed Web of Science ®Google Scholar
• Mohr DC, Likosky W, Boudewyn AC, Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998;4:487-9
   PubMed Web of Science ®Google Scholar
• Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 2009;23:453-62
   PubMed Web of Science ®Google Scholar
• Langner-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004;63:S35-41
   Web of Science ®Google Scholar
• Sandberg-Wollheim M, Bever C, Carter J, Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol 2005;252:8-13
   PubMed Web of Science ®Google Scholar
• Frohman E, Phillips T, Kokel K, Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-36
   PubMed Web of Science ®Google Scholar
• Cramer J, Rosenheck R, Kirk G, Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-73
   PubMed Web of Science ®Google Scholar
• Devonshire V. Adherence to disease-modifying therapy: recognizing the barriers and offering solutions. Ridgewood, NJ, Delaware Media Group, LLC; 2007
   Google Scholar
• Treadaway K, Cutter G, Salter A, Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, MacDonnell R, The Global Adherence Project (GAP) - a multicenter observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. Meeting Abstract, Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Madrid, Spain, 27 – 30 September 2006 [Poster P316]. Poster presented at ECTRIMS; 2006
   Google Scholar
• Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006;38:167-71
   PubMedGoogle Scholar
• Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 2003;35:163-70
   PubMedGoogle Scholar
• Turner AP, Williams RM, Sloan AP, Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol 2009;54:116-21
   PubMed Web of Science ®Google Scholar
• Sidorenko TV, Boyko AN, Davydovskaia MF, Adherence to long-term therapy with disease-modifying drugs. Zh Nevrol Psikhiatr Im S S Korsakova 2009;109:107-13
   PubMedGoogle Scholar
• Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 1997;120(Pt 2):289-97
   PubMedGoogle Scholar
• Rao SM, Leo GJ, Bernardin L, Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-91
   PubMed Web of Science ®Google Scholar
• Zakzanis KK. Distinct neurocognitive profiles in multiple sclerosis subtypes. Arch Clin Neuropsychol 2000;15:115-36
   PubMed Web of Science ®Google Scholar
• Assessment and management of cognitive impairment in multiple sclerosis. New York, NY: The National Clinical Advisory Board of the National Multiple Sclerosis Society. 2008. Available from: http://www.nationalmssociety.org/ download.aspx?id=124 [Last accessed 16 February 2010]
   Google Scholar
• Patti F, Amato MP, Bastianello S, Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010;16:68-77
   PubMed Web of Science ®Google Scholar
• Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005;76:469-75
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Likosky W, Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-3
   PubMed Web of Science ®Google Scholar
• Mohr DC, Likosky W, Bertagnolli A, Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol 2000;68:356-61
   PubMed Web of Science ®Google Scholar
• Jaber A, Bozzato GB, Vedrine L, A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol 2008;8:38
   PubMed Web of Science ®Google Scholar
• Cramer JA, Cuffel BJ, Divan V, Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006;113:156-62
   PubMed Web of Science ®Google Scholar
• Mikol D, Lopez-Bresnahan M, Taraskiewicz S, A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:585-91
   PubMed Web of Science ®Google Scholar
• Devonshire V. Delivery technology for multiple sclerosis therapy: an international, multicentre, single-arm, open-label, 12-week, phase IIIb trial of a new electronic device for subcutaneous injection of interferon beta-1a. Meeting Abstract, 19th Meeting of the European Neurological Society (ENS), Milan, Italy, 20-24 June 2009 [P698]. Poster presented at ENS: 2009
   Google Scholar
• Brearley C, Jaber A, Bertolino M, Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation. Int J Clin Pharmacol Ther 2007;45:307-18
   PubMed Web of Science ®Google Scholar
• Jaber A, Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 2007;43:1256-61
   PubMed Web of Science ®Google Scholar
• Bellomi F, Muto A, Palmieri G, Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiol 2007;30:241-6
   PubMed Web of Science ®Google Scholar
• Jaber A, Driebergen R, Giovannoni G, The Rebif new formulation story: it's not trials and error. Drugs R D 2007;8:335-48
   PubMedGoogle Scholar
• Giovannoni G, Barbarash O, Casset-Semanaz F, Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009;15:219-28
   PubMed Web of Science ®Google Scholar
• Camu W. Evaluating patient satisfaction on transition from subcutaneous interferon beta-1a to a new human serum albumin-free formulation: the TRANSFER study. Poster presented at the World Congress on Treatment and Research in Multiple Sclerosis [WCTRIMS], Montreal, Canada, 17 – 20 September 2008 [Poster P24]. Mult Scler 2008;14:S35
   PubMed Web of Science ®Google Scholar
• De Stefano N. Efficacy of a new formulation of subcutaneous interferon beta-1a in patients with relapsing-remitting multiple sclerosis: 16-week results from a double-blind, placebo-controlled study. Meeting Abstract, Annual Meeting of the American Academy of Neurology [AAN], Seattle, 25 April – 2 May 2009 [P07.145]. Neurology 2009;72:A359
   Web of Science ®Google Scholar
• Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004;101(Suppl 2):14599-606
   PubMedGoogle Scholar
• Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006;6:16-21
   PubMed Web of Science ®Google Scholar
• Cohen B. Adherence to disease-modifying therapy for multiple sclerosis. Int J MS Care 2006;(Suppl):32-7
   Google Scholar
• Byun E, Caillier SJ, Montalban X, Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008;65:337-44
   PubMed Web of Science ®Google Scholar